Kidney Cancer | Tumor

Immunotherapy Is 'Here to Stay' in Kidney Cancer

November 14th 2018

Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.

Distress Levels High Among Patients With Common Form of Kidney Cancer

November 8th 2018

Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.

A State of Flux for Kidney Cancer

November 6th 2018

Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.

Germline Mutations in Non-Clear Cell Renal Cell Carcinoma May Direct Systemic Therapy

October 16th 2018

More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.

New Approach May Spare Some with Kidney Cancer from Undergoing Surgery

October 16th 2018

Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.

NCCN Updates Guidelines for Kidney Cancer

October 15th 2018

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.

Cancer Researchers Win Nobel Prize

October 2nd 2018

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Monitoring Immunotherapy's Side Effects in Genitourinary Cancers

May 24th 2018

PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.

Immunotherapy in GU Cancers: Combinations Are the Next Step

May 4th 2018

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

FDA Approves Immunotherapy Duo for Kidney Cancer

April 16th 2018

The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

Patient Education Key in Flexible Dosing Schedule for Opdivo

March 22nd 2018

After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.

The Future of Kidney Cancer Management

March 8th 2018

Practical Advice for Patients With Kidney Cancer

March 8th 2018

Second-Line Therapeutic Options for Kidney Cancer

March 8th 2018

First-Line Kidney Cancer Treatment: Targeted Therapy

March 8th 2018

Kidney Cancer: Considering First-Line Treatment Options

March 8th 2018

Frontline Surgical Resection for Kidney Cancer

March 8th 2018

Approaching the Treatment of Kidney Cancer

March 8th 2018

Getting a Diagnosis for Kidney Cancer

March 8th 2018

Kidney Cancer Support & Resources

March 8th 2018

How Newer Treatment Options Work in Kidney Cancer

March 8th 2018

What to Know About Kidney Cancer Treatment

March 8th 2018

Recognizing the Different Types of Kidney Cancer

March 8th 2018

Patients Now Have the Option to Undergo Immunotherapy Less Frequently

March 6th 2018

The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.

FDA Grants Breakthrough Therapy Designation for Kidney Cancer Drug Combination

January 9th 2018

A new combination – Keytruda (pembrolizumab) plus Lenvima (lenvatinib) – was granted a breakthrough therapy designation to treat patients with advanced and/or metastatic renal cell carcinoma (RCC).

FDA Approves Frontline Cabometyx for Advanced Kidney Cancer

December 20th 2017

Cabometyx (cabozantinib) was granted approval by the Food and Drug Administration (FDA) for previously untreated patients who have advanced renal cell carcinoma (RCC).

FDA Grants Immunotherapy Duo a Priority Review for Kidney Cancer

December 14th 2017

Frontline Opdivo (nivolumab) plus Yervoy (ipilimumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat patients with intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).

FDA Expands Sutent Approval to Prevent Kidney Cancer Recurrence

November 17th 2017

The FDA approved Sutent to be used in patients who had a nephrectomy and are at high risk of their kidney cancer returning.

Managing Advanced Lung Cancer in the Future

November 13th 2017

Treatment Challenges in Advanced Lung Cancer

November 13th 2017